Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the m...
| Autor principal: | |
|---|---|
| Outros Autores: | , , |
| Formato: | article |
| Idioma: | eng |
| Publicado em: |
2019
|
| Assuntos: | |
| Texto completo: | https://doi.org/10.6061/clinics/2018/e450s |
| País: | Brasil |
| Oai: | oai:revistas.usp.br:article/154751 |